

GHIT Fund announces new investment worth 2.86B Yen

28 March 2019 | News

This includes three new projects and seven that will receive continued funding.



The Global Health Innovative Technology (GHIT) Fund has announced a total of 2.86 billion yen to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and schistosomiasis. This includes three new projects and seven that will receive continued funding.

Projects & Investments-

Treating schistosomiasis in preschool-aged children: development, registration and access to L-praziquantel orally disintegrating tablet formulation- **¥452,329,597**

Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes- **¥489,273,750**

Preclinical development of a novel mechanism-of-action antimalarial drug with multistage activity- **¥536,822,427**

Preclinical development of a new class of Plasmodium DHODH inhibitor for the treatment of malaria- **¥421,418,717**

Live attenuated prophylactic vaccine for leishmaniasis- **¥399,898,983**

Mitsubishi Tanabe Lead Optimization of Anti-Malarials- **¥192,247,534**

New Hit-to-Lead Activity for New Anti-Malarials between MMV and Takeda- **¥52,800,000**

Hit-to-Lead Development of Novel anti-TB Natural Products- **¥119,244,000**

Further development of a new asexual blood-stage malaria vaccine candidate- **¥93,057,133**

Development of LFA platform for improving sensitivity of Point-of-Care assays for infectious disease with main focus on Tuberculosis and Malaria- **¥100,000,000**